The pathogenic mechanisms of ApoB and ApoA-I suggest that the ratio represents a balance between pro- and anti-atherosclerotic, pro- and anti-inflammatory, and thrombotic and antithrombotic lipoprotein particles and has great clinical application in stroke risk assessment and targeted therapy. This evidence concerns the gene APOB and stroke disorder.